$150.00 – $2,200.00
BUY SGT-78 CANNABINOIDS ONLINE
Synthetic cannabinoids like SGT-78 have a fairly low specificity. However, they are powerful agonists of both the CB1 and CB2 receptors in test subjects.
SGT-78 is chemically similar to 5F-Cumyl-PINACA, except that the alkyl chain terminates in a cyano group. The extent to which this can metabolize into cyanide in living subjects is not fully understood.
This product should be stored in a dry, cool location, and should retain full potency for at least 2 years if stored properly.
This chemical is not intended for human consumption. Also, it should not be handled by untrained personnel or without proper safety equipment. It is sold as a research chemical, for laboratory use only.
4-CN-CUMYL-BUTINACA has been encountered in
numerous synthetic cannabinoid products that are smoked for
their psychoactive effects
Information on user population in the U.S. is limited. 4-CNCUMYL-BUTINACA abuse is not monitored by any national
drug abuse surveys. Poison control centers continue to report
adverse health effects in response to the abuse of synthetic
cannabinoids and this abuse is both a public health and safety
concern. Serious adverse effects including death have been
reported following the use of 4-CN-CUMYL-BUTINACA.
The National Forensic Laboratory Information System
(NFLIS), a system that collects drug analysis information from
state and local forensic laboratories, contain 654 reports for 4-
CN-CUMYL-BUTINACA between 2016 and 2018.
4-CN-CUMYL-BUTINACA is a Schedule I controlled
substance under the Federal Controlled Substances Act.
4-CN-CUMYL-BUTINACA is classified as an indazole.
4-CN-CUMYL-BUTINACA is based on an indazole core
structure where the 1- and 3-positions of the indazole ring
system are substituted. The 1-position of 4-CN-CUMYLBUTINACA is substituted with a linear four carbon chain
terminated with a cyano (CN) group. The 3-position is
substituted with an amide linker, and the nitrogen atom (N)
of this linker is further substituted with a 2-phenyl-propan-2-
Data from preclinical studies show that 4-CN-CUMYLBUTINACA binds to and acts as an agonist at the CB1
There are no published studies on the safety of 4-CNCUMYL-BUTINACA for human use.